Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals          下载免费PDF全文

K. D. MacDonald  K. A. Hart  J. L. Davis  L. J. Berghaus  S. Giguère 《Equine veterinary journal》2018,50(4):532-536

  相似文献   

Letter to the Editor: Do we have to redefine lameness in the era of quantitative gait analysis?          下载免费PDF全文

A. P. Bathe  C. E. Judy  S. Dyson 《Equine veterinary journal》2018,50(2):273-273

  相似文献   

Comparison of aloe vera and omeprazole in the treatment of equine gastric ulcer syndrome          下载免费PDF全文

J. Bush  R. van den Boom  S. Franklin 《Equine veterinary journal》2018,50(1):34-40

  相似文献   

Validation of biplane high‐speed fluoroscopy combined with two different noninvasive tracking methodologies for measuring in vivo distal limb kinematics of the horse          下载免费PDF全文

S. M. Geiger  E. Reich  P. Böttcher  S. Grund  J. Hagen 《Equine veterinary journal》2018,50(2):261-269

  相似文献   

Effect of age and dietary carbohydrate profiles on glucose and insulin dynamics in horses          下载免费PDF全文

S. I. Jacob  R. J. Geor  P. S. D. Weber  P. A. Harris  M. E. McCue 《Equine veterinary journal》2018,50(2):249-254

  相似文献   

Proximal suspensory desmopathy in hindlimbs: Magnetic resonance imaging,gross post‐mortem and histological study          下载免费PDF全文

S. Dyson  M. J. Pinilla  N. Bolas  R. Murray 《Equine veterinary journal》2018,50(2):159-165

  相似文献   

Elapid snake envenomation in horses: 52 cases (2006–2016)          下载免费PDF全文

N. J. Bamford  S. B. Sprinkle  L. A. Cudmore  A. M. Cullimore  A. W. van Eps  E. J. M. M. Verdegaal  B. S. Tennent‐Brown 《Equine veterinary journal》2018,50(2):196-201

  相似文献   

Use of quantitative real‐time PCR to determine viability of Streptococcus equi subspecies equi in respiratory secretions from horses with strangles          下载免费PDF全文

N. Pusterla  C. M. Leutenegger  S. M. Barnum  B. A. Byrne 《Equine veterinary journal》2018,50(5):697-700

  相似文献   

Sedative and cardiorespiratory effects of low doses of xylazine with and without acepromazine in Nordestino donkeys          下载免费PDF全文

J. A. Lucas Castillo  M. Gozalo‐Marcilla  M. Werneck Fonseca  F. S. Possebon  A. C. da Rosa  A. J. de Araujo Aguiar 《Equine veterinary journal》2018,50(6):831-835

  相似文献   

Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin          下载免费PDF全文

C.J. Henry  B.K. Flesner  S.A. Bechtel  J.N. Bryan  D.J. Tate  K.A. Selting  J.C. Lattimer  M.E. Bryan  L. Grubb  F. Hausheer 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2018,32(1):370-376

Background

Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion/diuresis volume in clinical trials in humans.

Hypothesis/Objectives

We hypothesized that Tavocept would decrease diuresis volume and time and facilitate safe administration of a cisplatin/piroxicam protocol to dogs with bladder cancer. Secondary objectives were to compare response rate and survival times to an historical comparator group treated without Tavocept.

Animals

Fourteen client‐owned dogs were prospectively enrolled.

Methods

Tumor volume was measured by computed tomography at days 0, 42, and 84. Dogs received combination Tavocept/cisplatin with a shortened diuresis protocol. A total of 4 doses was planned, with concurrent administration of piroxicam. Serial biochemical analyses were evaluated for azotemia.

Results

A 90‐minute infusion/diuresis time was used for all dogs. Three dogs (21%) had concurrent increases in serum creatinine (>2.0 mg/dL) and BUN (>42 mg/dL) concentrations; 2 of these dogs were isosthenuric. This frequency of nephrotoxicity is significantly less (P = 0.0406) than that of an historical control group treated without Tavocept. Overall response rate was 27%. Median survival time was comparable to historical controls (253 vs. 246 days).

Conclusions and Clinical Importance

Tavocept decreased the required diuresis time with cisplatin from > 6 hours to 90 minutes, while also decreasing occurrence of azotemia. Survival time was comparable, but the response rate was inferior to an historical comparator group. Further evaluation in other tumors susceptible to platinum agents is warranted.  相似文献